Pablo Cabral
Executive Director, External Innovation Eli Lilly
Seminars
Tuesday 17th March 2026
Panel Discussion: What Does Cardiorenal Mean to You? Defining Cardiorenal in a Rapidly Evolving Therapeutic Landscape
8:00 am
- Exploring different definitions of cardiorenal across clinical practice, research, and industry
- Identifying patient populations at highest risk and challenges in consistent diagnosis
- Examining whether cardiorenal primarily reflects CKD-driven CV risk, heart failure overlap, or a broader spectrum
- Considering how pharma, academia, and clinicians can align on trial design and endpoints for cardiorenal therapies
Wednesday 18th March 2026
Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?
10:30 am
- Balancing innovation with clinical feasibility and scalable development in kidney disease
- Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
- Exploring whether targeted delivery strategies must be disease-specific to maximize impact
- Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown
